The main risk is sequencing. Palladyne needs
backlog conversion, field proof, follow-on procurement, improving mix, and financing discipline to happen in roughly the right order. If validation stays stuck in exercises, or if
cash burn forces repeated
dilution before repeat programs arrive, enterprise progress may not translate into attractive per-share compounding.